Cyclo Therapeutics Inc <CYTH.OQ> expected to post a loss of 16 cents a share - Earnings Preview
Cyclo Therapeutics Inc CYTH.OQ CYTH.O is expected to show a rise in quarterly revenue when it reports results on March 17 (estimated) for the period ending December 31 2024
The Gainesville Florida Florida-based company is expected to report a 3.5% increase in revenue to $322 thousand from $311 thousand a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Cyclo Therapeutics Inc is for a loss of 16 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Cyclo Therapeutics Inc is $0.95, above its last closing price of $0.70.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.16 | -0.16 | -0.27 | Missed | -72.3 |
Jun. 30 2024 | -0.15 | -0.15 | -0.21 | Missed | -35.5 |
Mar. 31 2024 | -0.20 | -0.20 | -0.15 | Beat | 26.8 |
-0.34 | |||||
| -0.29 | ||||
Jun. 30 2023 | -0.44 | -0.33 | Beat | 25 | |
Mar. 31 2023 | -0.42 | -0.42 | -0.46 | Missed | -9.5 |
Dec. 31 2022 | -0.25 | -0.59 | Missed | -136 |
This summary was machine generated March 14 at 11:42 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
